Cancer clinical trials in the region Pays de la Loire

433 currently recruiting clinical trials
Region Pays de la Loire
Phase 1 / Phase 2 Breast cancer #NCT06907043 #2024-520395-99-00
Cohorte Cancer du sein
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
BRCA 1/2 PALB2 ATM Other mutation CHEK 1/2
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at localized stage
Chemotherapy
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Chemotherapy
2 recruiting sites
Eikon Therapeutics
Phase 1 / Phase 2 Pancreas cancer #NCT06907043 #2024-520395-99-00
Cohorte cancer du pancréas
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
BRCA 1/2 PALB2 ATM Other mutation CHEK 1/2
Required number of previous lines of therapy for current stage of disease
1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
Eikon Therapeutics
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06265727
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
Other mutation
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Corbus Pharmaceuticals Inc.
Phase 1 / Phase 2 Ovarian / Fallopian tubes / Peritoneum cancer #NCT06888921 #2025-521125-33-00
Required histologic types
Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC)
Required number of previous lines of therapy for current stage of disease
2 3 or more
Required platino resistance
Recurrence 6 months or more after platinum treatme...
Required previous treatments at localized stage
Chemotherapy
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Immunotherapy
8 recruiting sites
Compugen Ltd
Phase 1 / Phase 2 Lymphoma #NCT05607420 #2022-501607-27-00
Partie escalade de dose
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma Primary mediastinal lymphoma Mantel cell lymphoma Follicular lymphoma Marginal zone lymphoma MALT lymphoma Indolent transformed lymphoma
Required central nervous system lesions
None
Required number of previous lines of therapy
2 3 or more
Required previous treatments
Chemotherapy Monoclonal antibodies
Excluded previous treatments
Systemic Treatment-Naive Car-T
4 recruiting sites
Cellectis SA
Phase 1 / Phase 2 Lymphoma #NCT05607420 #2022-501607-27-00
Partie extension de dose
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma Follicular lymphoma Indolent transformed lymphoma
Required central nervous system lesions
None
Required number of previous lines of therapy
2 3 or more
Required previous treatments
Chemotherapy Monoclonal antibodies
Excluded previous treatments
Systemic Treatment-Naive Car-T
4 recruiting sites
Cellectis SA
Phase 1 / Phase 2 Lung cancer #NCT06362252 #2023-509629-36-00
Cohorte 1 (Maintenance)
Required histologic types
SCLC (Small Cell Lung Cancer)
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy
8 recruiting sites
Daiichi Sankyo
Phase 1 / Phase 2 Colon cancer Rectal cancer #NCT06923761 #2023-504845-30-00
Module 2 Partie D cancer colorectal pMMR/MSS
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
MSS/pMMR
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
Grey Wolf Therapeutics
Phase 1 / Phase 2 Lung cancer #NCT06669117 #2024-512760-64-00
Parties 2a et 2b
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
MET
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Laboratoires Pierre Fabre
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06669117 #2024-512760-64-00
Partie 1 (Escalade de dose)
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
MET
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Laboratoires Pierre Fabre